**Core tip:** Cetuximab in combination with oral fluoropyrimidine (FP) remains controversial in metastatic colorectal cancer. A retrospective cohort analysis was performed to compare oral FP with infusional FP in combination with cetuximab in Chinese population in the real-world setting. Our analysis demonstrated comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP. Thus, oral FP-based chemotherapy should be considered as a valid option in Chinese patients receiving cetuximab.

INTRODUCTION
============

Addition of cetuximab, an anti-epidermal growth factor receptor monoclonal antibody (anti-*EGFR* mAb), to the standard chemotherapy regimens has been shown to improve outcomes for *RAS* wild-type metastatic colorectal cancer (mCRC)\[[@B1]-[@B3]\] and this has been the standard of care recommendation in various regional and international guidelines\[[@B4],[@B5]\].

At present, no chemotherapy backbone was clearly known to be superior to one another when combined with cetuximab. However, the efficacy of cetuximab in combination with oral fluoropyrimidine (FP)-based chemotherapy is controversial\[[@B6]-[@B8]\]. In the subgroup analysis of the phase III MRC COIN trial, survival benefits of cetuximab were only demonstrated when combined with infusional FP but not oral FP. One of the postulations was that the dose intensity of the chemotherapy regimen was more likely to be compromised in patients receiving both oral FP-based chemotherapy and cetuximab due to overlapping treatment toxicities, notably diarrhoea. The average duration of treatment for patients treated with oral FP-based chemotherapy plus cetuximab was also shorter. On the contrary, this phenomenon was not observed among patients who received infusional FP\[[@B6]\]. These findings are also consistent with subsequent meta-analyses of multiple randomized controlled trials\[[@B7],[@B8]\]. Therefore, the use of oral FP-based chemotherapy in combination with anti-*EGFR* mAb is not recommended in various regional and international guidelines\[[@B4],[@B5]\].

Yet, it has been shown that there exist regional differences for the tolerability profile of FP and East Asians appear to tolerate FP the best\[[@B9]\]. With this in mind, the lack of efficacy of cetuximab when combining with capecitabine-based chemotherapy observed in the MRC COIN trial, in which most participants were Caucasians, may not be applicable to East Asians. This concurs with the findings of the FLEET study, a non-randomized multicenter phase II study conducted in Japan, which demonstrated similar safety and efficacy of XELOX or FOLFOX plus cetuximab as the first-line therapy in mCRC\[[@B10],[@B11]\].

The demonstration of non-inferiority of oral FP versus infusional FP in combination with cetuximab carries important implications as oral FP offers potential advantages over infusional FP. First, oral FP is more cost effective with lower direct cost\[[@B12],[@B13]\]. Second, studies also showed higher patient preference for oral FP as it is more convenient and reduces the need of hospital admission\[[@B13],[@B14]\].

In view of the above, we conducted a retrospective cohort analysis to compare the efficacy and safety profile of cetuximab in combination with oral FP and infusional FP in Chinese population in the real-world setting.

MATERIALS AND METHODS
=====================

Study design, setting, and patient population
---------------------------------------------

This study was a single institutional retrospective cohort analysis. The treatment records of all patients with mCRC who were treated between January 2010 to December 2015 at the Department of Clinical Oncology, Queen Mary Hospital, Hong Kong were screened. Patients were eligible for further analysis if they fulfilled the following criteria: Histologically confirmed colorectal adenocarcinoma; known wild-type *KRAS* (*NRAS* has to be wild-type if the status was known); received first-line treatment with cetuximab-based therapy; FP-based chemotherapy backbone; and complete clinical and follow-up data available. Patients with co-existing active malignancy were excluded. This study was approved by the institutional review board (HKU/HA HKW IRB UW 15-315) and the research was reported according to the STROBE statement.

Data collection and study objectives
------------------------------------

Eligible patients were divided into two groups according to chemotherapy backbone, namely, an oral FP group and an infusional FP group (Table [1](#T1){ref-type="table"}). Baseline characteristics of the two groups of patients including age, gender, and disease characteristics such as site of primary tumor were recorded. Treatment characteristics including number of treatment cycles and treatment modification were also recorded.

###### 

The schedules of chemotherapy regimens

  ------------------------------------------------------------------------------------------------------------------
  **Oral fluoropyrimidine-based regimen[1](#T1FN1){ref-type="table-fn"}^,^[3](#T1FN3){ref-type="table-fn"}**
  *Cetuximab + CAPOX every 3 wk*
  Cetuximab: 500 mg/m^2^ on day 1 and 250 mg/m^2^ on day 15
  Oxaliplatin: 130 mg/m^2^ on day 1
  Capecitabine: 1000 mg/m^2^ from day 1 to day 14
  *Cetuximab + CAPIRI every 3 wk*
  Cetuximab: 500 mg/m^2^ on day 1 and 250 mg/m^2^ on day 15
  Irinotecan: 200 mg/m^2^ on day 1
  Capecitabine: 800 mg/m^2^ from day 1 to day 14
  **Infusional fluoropyrimidine-based regimen[2](#T1FN2){ref-type="table-fn"}^,^[3](#T1FN3){ref-type="table-fn"}**
  *Cetuximab + FOLFOX every 2 wk*
  Cetuximab: 500 mg/m^2^ on day 1
  Oxaliplatin: 85 mg/ m^2^ on day 1
  Leucovorin: 200 mg/m^2^ over 2 h on day 1 and 2
  5-Fluorouracil: 400 mg/m^2^ bolus on day 1 and 2
  5-Fluorouracil: 600 mg/m^2^ over 20 h on day 1 and 22 h on day 2
  *Cetuximab + FOLFIRI every 2 wk*
  Cetuximab: 500 mg/m^2^ on day 1
  Irinotecan: 180 mg/ m^2^ on day 1
  Leucovorin: 200 mg/m^2^ over 2 h on day 1 and 2
  5-Fluorouracil: 400 mg/m^2^ bolus on day 1 and 2
  5-Fluorouracil: 600 mg/m2 over 20 h on day 1 and 22 h on day 2
  ------------------------------------------------------------------------------------------------------------------

In brief, treatment has to be withheld for grade 2 or above toxicities and to be resumed once recovered to grade 1. Dose reduction was considered for recurrent grade 2, or grade 3 or above toxicities.

75% dose of the regimen would be used if patients were older than 70 years old and 75% dose of capecitabine if creatinine clearance was less than 50 mL/min;

75% dose of the regimen would be used if patients were older than 70 years old;

Dose modification of chemotherapy due to toxicities was performed according to standard practice.

The primary outcome measures of this study were the median progression-free survival (mPFS) and median overall survival (mOS). Progression-free survival (PFS) was defined as the duration between treatment initiation and tumor progression or death from any cause, whichever was earlier, while overall survival (OS) was deﬁned as the duration between treatment initiation to death from any cause. Patients known to be alive or lost to follow-up at the time of analysis were censored at their last follow-up. The secondary outcome measures of this study were safety profiles of cetuximab plus different chemotherapy backbones. The adverse events were graded according to the Common Terminology Criteria for Adverse Events version 4.0. Our study also included exploratory analysis to investigate the effects of different predictors of outcomes and their interaction with the chemotherapy backbones.

Statistical analysis
--------------------

Categorical outcomes were compared using Fisher's exact test or chi-squared test, while continuous outcomes were assessed by two-sample unpaired *t*-test. OS and PFS were calculated by Kaplan-Meier analysis and the survival curves were compared by log-rank test. Cox regression analysis was used for both univariable and multivariable analysis for factors associated with survival. All *P*-values less than 0.05 were considered statistically significant. Statistical analyses were carried out using R version 3.3.2.

RESULTS
=======

Figure [1](#F1){ref-type="fig"} illustrates the number of patients at different stages of study enrollment. One hundred patients with mCRC received first-line treatment with cetuximab and FP-based therapy between January 2010 to December 2015 at the Department of Clinical Oncology, Queen Mary Hospital. A total of 95 patients were eligible for analysis in this study, and the median follow-up period of the surviving patients was 65.0 mo \[Interquartile range (IQR): 55.3--86.1\]. Ninety-four patients progressed after the first-line treatment and eighty-nine patients have passed away at the time of analysis.

![Study design.](WJGO-11-1031-g001){#F1}

The baseline characteristics of eligible patients are shown in Table [2](#T2){ref-type="table"}. The median age at the start of the first-line chemotherapy of all eligible patients was 61.0 years (IQR: 53.5--68.0 years). No signiﬁcant differences were recognized in the distribution of the baseline patient characteristics between the oral and infusional FP groups. With regard to the clinical characteristics and extent of the disease, the two groups of patients were comparable in terms of site of primary tumour, resection of primary tumour, timing of the metastasis, and extent of metastasis.

###### 

Baseline characteristics of eligible patients

                                                     **Total (*n* = 95)**   **Oral (*n* = 57)**   **Infusional (*n* = 38)**   ***P* value**
  -------------------------------------------------- ---------------------- --------------------- --------------------------- ---------------
  Gender (%)                                                                                                                  
  Male                                               52 (54.7)              32 (56.1)             20 (52.6)                   0.900
  Age (yr)                                                                                                                    
  Median                                             61.0                   61.0                  61.0                        0.622
  Age ≥ 70 (%)                                       21 (22.1)              12 (21.1)             9 (23.7)                    0.960
  ECOG performance status                                                                                                     
  0                                                  7 (7.4)                4 (7.0)               3 (7.9)                     0.383
  1                                                  80 (84.2)              50 (87.7)             30 (78.9)                   
  2                                                  8 (8.4)                3 (5.3)               5 (13.2)                    
  3                                                  0 (0)                  0 (0)                 0 (0)                       
  4                                                  0 (0)                  0 (0)                 0 (0)                       
  Site of primary tumor (%)                                                                                                   
  Right-sided colon                                  20 (21.1)              15 (26.3)             5 (13.2)                    0.114
  Left-sided colon                                   49 (51.6)              25 (43.9)             24 (63.2)                   
  Rectum                                             22 (23.2)              13 (22.8)             9 (23.7)                    
  Multiple                                           4 (4.2)                4 (7.0)               0 (0.0)                     
  Timing of metastasis (%)                                                                                                    
  Synchronous                                        72 (75.8)              40 (70.2)             32 (84.2)                   0.187
  Metachronous                                       23 (24.2)              17 (29.8)             6 (15.8)                    
  Extent of the disease (%)                                                                                                   
  Primary resected[1](#T2FN1){ref-type="table-fn"}   68 (71.6)              42 (73.7)             26 (68.4)                   0.745
  Liver-only metastatsis                             44 (46.3)              26 (45.6)             18 (47.4)                   1.000
  \> 1 site of metastasis                            40 (42.1)              24 (42.1)             16 (42.1)                   1.000
  Site of metastasis (%)                                                                                                      
  Liver                                              67 (70.5)              39 (68.4)             28 (73.7)                   
  Lymph Nodes                                        28 (29.5)              17 (29.8)             11 (28.9)                   
  Peritoneum                                         21 (22.1)              11 (19.3)             10 (26.3)                   
  Lung                                               17 (17.9)              11 (19.3)             6 (15.8)                    
  Bone                                               3 (3.2)                2 (3.5)               1 (2.6)                     
  Others                                             8 (8.4)                6 (10.5)              2 (5.3)                     

No signiﬁcant differences were recognized in the distribution of the baseline patient characteristics between the oral and infusional fluoropyrimidine groups. With regard to the clinical characteristics of the disease and extent of disease, the two groups of patients were comparable in terms of site of primary tumour, resection of primary tumour, timing of the metastasis, and proportion of liver-only disease.

Include both palliative surgery of primary and previous surgery of nonmetastatic patients.

Table [3](#T3){ref-type="table"} summarizes the first-line chemotherapy regimens received by eligible patients. Fifty-seven (60.0%) patients received capecitabine, an oral FP, while thirty-eight (40.0%) received intravenous infusion of 5-fluorouracil (infusional FP). Oxaliplatin (76.7%) was more commonly used as the partner of fluoropyrimidine in our cohort, compared to irinotecan (23.3%). There was no statistically significant difference in the proportions of patients receiving treatment modification of the first-line treatment, metastasectomy of curative intent, subsequent systemic therapy, and the mean treatment durations in the two treatment groups.

###### 

Treatment characteristics of eligible patients

                                                              **Total (*n* = 95)**   **Oral (*n* = 57)**   **Infusional (*n* = 38)**   ***P* value**
  ----------------------------------------------------------- ---------------------- --------------------- --------------------------- ---------------
  Chemotherapy backbone (%)[1](#T3FN1){ref-type="table-fn"}                                                                            
  FOLFOX                                                      26 (27.4)              0 (0)                 26 (68.4)                   
  CAPOX                                                       43 (45.3)              43 (75.4)             0 (0)                       
  FOLFIRI                                                     12 (12.6)              0 (0)                 12 (31.6)                   
  CAPIRI                                                      9 (9.5)                9 (15.8)              0 (0)                       
  Capecitabine                                                5 (5.3)                5 (8.8)               0 (0)                       
  Type of fluoropyrimidine (%)                                                                                                         
  Oral                                                        57 (60.0)              57 (100)              0 (0)                       
  Infusional                                                  38 (40.0)              0 (0)                 38 (100)                    
  Chemotherapy partner (%)                                                                                                             
  Oxaliplatin                                                 69 (76.7)              43 (75.4)             26 (68.4)                   0.184
  Irinotecan                                                  21 (23.3)              9 (15.8)              12 (31.6)                   
  Mean treatment duration                                                                                                              
  Oral/Infusional FP (wk)[2](#T3FN2){ref-type="table-fn"}     18.5                   19.4                  17.2                        0.147
  Any treatment modification (%)                                                                                                       
  Yes                                                         75 (78.9)              43 (75.4)             32 (84.2)                   0.441
  Due to age                                                  21 (22.1)              12 (21.1)             9 (23.7)                    
  Due to adverse effects                                      54 (56.8)              31 (54.4)             23 (60.5)                   
  Subsequent systemic therapy (%)                                                                                                      
  Yes                                                         65 (68.4)              40 (70.2)             25 (65.8)                   0.822
  Metastasectomy of curative intent (%)                                                                                                
  Yes                                                         16 (16.8)              6 (10.5)              10 (26.3)                   0.083

There was no statistically significant difference in the proportions of patients receiving treatment modification of the first-line treatment, metastasectomy of curative intent, subsequent systemic therapy, and the mean treatment durations in the two treatment groups.

The details of the regimen are shown in Table [1](#T1){ref-type="table"};

FP refers to fluoropyrimidine.

Kaplan-Meier analysis of the PFS and OS of all eligible patients and the two treatment groups is presented in Figure [2](#F2){ref-type="fig"}. The mPFS of the entire cohort was 9.66 mo (95%CI: 7.72--12.5). There was no statistical difference in the mPFS between the oral FP group and infusional FP group (9.79 mo \[95%CI: 7.49--12.7\] *vs* 9.63 mo \[95%CI: 6.34--13.4\]; log-rank *P* = 0.72; Figure [2A](#F2){ref-type="fig"}). The mOS of the entire cohort was 25.8 mo (95%CI: 18.7--35.6) and there was also no statistical difference between the oral FP group and infusional FP group \[25.8 mo (95%CI: 15.2--35.6) *vs* 26.3 mo (95%CI: 18.7-41.2), log-rank *P* = 0.63, Figure [2B](#F2){ref-type="fig"}\]. Among the twelve 5-year survivors, all of them had resection of primary tumor and ten (83.3%) of them had left-sided tumor and synchronous metastasis, respectively. Eight (66.7%) patients had metastasis limited to the liver only and four (33.3%) of them had resection of liver metastasis with curative intent.

![Kaplan-Meier curves for progression free survival (A, left) and overall survival (B, right) according to treatment groups. A: The median progression free survival (mPFS) of the entire cohort was 9.66 mo (95%CI: 7.72--12.5) and there was no statistical difference in mPFS between the oral fluoropyrimidine (FP) group and infusional FP group \[9.79 mo (95%CI: 7.49--12.7) *vs* 9.63 mo (95%CI: 6.34--13.4); log-rank *P* = 0.72\]; B: The median overall survival (mOS) of the entire cohort was 25.8 mo (95%CI: 18.7--35.6) and there was no statistical difference between the oral FP group and infusional FP group \[25.8 mo (95%CI: 15.2--35.6) *vs* 26.3 mo (95%CI: 18.7--41.2); log-rank *P* = 0.63\].](WJGO-11-1031-g002){#F2}

Cox regression analysis was performed to evaluate the impact of various baseline and treatment characteristics on PFS and OS of eligible patients. The crude and adjusted hazard ratios (HR) of different predictors of PFS are presented in Table [4](#T4){ref-type="table"}, while the crude and adjusted HR of different predictors of OS are presented in Table [5](#T5){ref-type="table"}. It was shown that right-sided primary tumor confered poorer PFS (adjusted HR = 1.87, 95%CI: 1.08--3.25, *P* = 0.03) and OS (adjusted HR = 1.92, 95%CI: 1.10--3.36, *P* = 0.02), compared to left-sided primary tumor. On the contrary, primary tumor resection improved the outcomes of patients in terms of both PFS (adjusted HR = 0.35, 95%CI: 0.21--0.59, *P* \< 0.01) and OS (adjusted HR = 0.37, 95%CI: 0.22--0.62, *P* \< 0.01). As for the chemotherapy backbone, oral FP-based chemotherapy did not appear to impact on the PFS (adjusted HR = 1.00, 95%CI: 0.63--1.57, *P* = 0.99) and OS (adjusted HR = 0.87, 95%CI: 0.56--1.37, *P* = 0.56) of patients receiving cetuximab as compared to infusional FP-based chemotherapy. Other predictors in the model did not have significant effects on the PFS and OS. The results of the subgroup analysis are shown in Figure [3](#F3){ref-type="fig"}. In the subgroup analysis, age group was shown to modify the effects of chemotherapy backbone on PFS (*P* = 0.007, Figure [3A](#F3){ref-type="fig"}) and a similar trend was observed in OS (*P* = 0.050, Figure [3B](#F3){ref-type="fig"}). However, no particular subgroup was identified to have more benefit with either oral or infusional FP regimen.

![Exploratory predictive factor analyses for progression-free survival (A, above) and overall survival (B, below). A: Age group was shown to modify the effects of chemotherapy backbone on progression-free survival (*P* = 0.007); B: A similar trend was observed in overall survival (*P* = 0.050).](WJGO-11-1031-g003){#F3}

###### 

Cox regression analysis for the effects of different predictors on progression-free survival

  **Factor**                                      **Crude HR (95%CI)**   **Adjusted HR (95%CI)**   ***P* value[1](#T4FN1){ref-type="table-fn"}**
  ----------------------------------------------- ---------------------- ------------------------- -----------------------------------------------
  Age                                             1.00 (0.98-1.02)       1.00 (0.98-1.02)          0.909
  Male                                            0.91 (0.60-1.38)       1.00 (0.64-1.54)          0.985
  Right sided primary                             1.63 (0.97-2.74)       1.87 (1.08-3.25)          [a](#T4FN3){ref-type="table-fn"}0.026
  Primary resected                                0.39 (0.24-0.63)       0.35 (0.21-0.59)          [b](#T4FN4){ref-type="table-fn"}\<0.001
  Liver only disease                              0.56 (0.37-0.86)       0.57 (0.36-0.91)          [c](#T4FN5){ref-type="table-fn"}0.019
  Infusional FP[2](#T4FN2){ref-type="table-fn"}   0.92 (0.60-1.42)       1.00 (0.63-1.57)          0.992

It refers to the *P-*values for multivariable Cox regression analysis (*i.e*., adjusted HR);

FP refers to fluoropyrimidine.

*P*: Right sided primary;

*P*: Primary resected;

*P*: Liver-only disease.

###### 

Cox regression analysis for the effects of different predictors on overall survival

  **Factor**                                      **Crude HR (95%CI)**   **Adjusted HR (95%CI)**   ***P* value[1](#T5FN1){ref-type="table-fn"}**
  ----------------------------------------------- ---------------------- ------------------------- -----------------------------------------------
  Age                                             1.01 (0.99-1.03)       1.01 (0.99-1.03)          0.394
  Male                                            0.86 (0.56-1.31)       1.04 (0.67-1.63)          0.848
  Right sided primary                             1.96 (1.16-3.31)       1.92 (1.10-3.36)          [a](#T5FN3){ref-type="table-fn"}0.023
  Primary resected                                0.34 (0.21-0.55)       0.37 (0.22-0.62)          [b](#T5FN4){ref-type="table-fn"}\<0.001
  Liver only disease                              0.54 (0.35-0.83)       0.58 (0.36-0.95)          [c](#T5FN5){ref-type="table-fn"}0.029
  Infusional FP[2](#T5FN2){ref-type="table-fn"}   0.90 (0.58-1.39)       0.87 (0.56-1.37)          0.558

It refers to the *P-*values for multivariable Cox regression analysis (*i.e*., adjusted HR);

FP refers to fluoropyrimidine.

*P*: Right sided primary;

*P*: Primary resected;

*P*: Liver-only disease.

The frequency of adverse events in different treatment groups is shown in Table [6](#T6){ref-type="table"}. Twenty-seven (28.4%) patients experienced adverse events of grade 3 or above with the two commonest adverse events being neutropenia (10.5%) and thrombocytopenia (5.3%). No significant difference was noted in the toxicity profiles of the two treatment groups.

###### 

Grade 3 or above adverse events experienced by our patients

                                                                   **Total (*n* = 95)**   **Oral (*n* = 57)**   **Infusional (*n* = 38)**   ***P* value**
  ---------------------------------------------------------------- ---------------------- --------------------- --------------------------- ---------------
  Any adverse events (%)                                           95 (100)               57 (100)              38 (100)                    1.000
  G3 or above adverse events (%)[1](#T6FN1){ref-type="table-fn"}   27 (28.4)              19 (33.3)             8 (21.1)                    0.286
  Hematologic (%)                                                                                                                           
  Anaemia                                                          64 (67.4)              36 (63.2)             28 (73.7)                   0.396
  G3 or above                                                      4 (4.2)                4 (7.0)               0 (0)                       0.147
  Leucopenia                                                       44 (46.3)              25 (43.9)             19 (50.0)                   0.705
  G3 or above                                                      3 (3.2)                1 (1.8)               2 (5.3)                     0.562
  Neutropenia                                                      49 (51.6)              26 (45.6)             23 (60.5)                   0.224
  G3 or above                                                      10 (10.5)              5 (8.8)               5 (13.2)                    0.514
  Thrombocytopenia                                                 53 (55.8)              37 (64.9)             16 (42.1)                   0.047 ^a^
  G3 or above                                                      5 (5.3)                5 (8.8)               0 (0)                       0.081
  Biochemistry (%)                                                                                                                          
  Raised AST                                                       68 (71.6)              47 (82.5)             21 (55.3)                   0.008 ^b^
  G3 or above                                                      2 (2.1)                1 (1.8)               1 (2.6)                     1.000
  Raised bilirubin                                                 21 (22.1)              14 (24.6)             7 (18.4)                    0.650
  G3 or above                                                      2 (2.1)                1 (1.8)               1 (2.6)                     1.000
  Non-hematologic (%)                                                                                                                       
  Acneiform rash                                                   58 (61.1)              36 (63.2)             22 (57.9)                   0.764
  G3 or above                                                      3 (3.2)                1 (1.8)               2 (5.3)                     0.562
  Diarrhoea                                                        25 (26.3)              17 (29.8)             8 (21.1)                    0.476
  G3 or above                                                      2 (2.1)                2 (3.5)               0 (0)                       0.515
  Hand-foot syndrome                                               2 (2.1)                2 (3.5)               0 (0)                       0.515
  G3 or above                                                      2 (2.1)                2 (3.5)               0 (0)                       0.515

The incidence of thrombocytopenia^a^ and raised AST^b^ was significantly higher in the oral FU group. No significant difference was noted in the grade 3 or above adverse effects between the two treatment groups.

G3 refers to grade 3.

DISCUSSION
==========

The results of the current study demonstrated the real-world efficacy and safety of oral FP-based chemotherapy in combination with cetuximab in Chinese population, compared with infusional FP-based chemotherapy. The mPFS and mOS of the patients in our study, in which both infusional and oral FP were used, were 9.66 mo (95%CI: 7.72--12.5) and 25.8 mo (95%CI: 18.7--35.6), respectively. These findings are comparable to those reported in other landmark trials using infusional FP plus cetuximab in *KRAS* wild-type mCRC\[[@B1],[@B2]\]. More importantly, cetuximab plus oral FP-based chemotherapy achieved similar outcomes to infusional FP-based chemotherapy. Hence, in contrast to Caucasian patients, oral FP-based chemotherapy should still be considered as a valid option in Chinese patients receiving cetuximab. Albeit the slight difference in dosing schedule, this is consistent with the findings of the FLEET and FLEET2 studies conducted in Japan which demonstrated the validity of combining cetuximab with XELOX\[[@B10],[@B11]\]. In our study, we also performed a subgroup analysis for the effects of oral FP versus infusional FP on PFS and OS. Although no subgroup was identified to have more benefit with either regimen, age group may potentially modify the effects on PFS (*P* = 0.007). The interaction was still significant after adjusting *P*-values by Bonferroni correction for multiple testing. The lack of significant effects of different FP-based chemotherapy in the two age groups may be accounted by inadequate power of the subgroup analysis due to limited sample size in each subgroup (74 patients aged below 70 *vs* 21 patients aged 70 or above). Moreover, the significant interaction may be related to the upfront dose reduction of the chemotherapy regimen. As the subgroup analysis was exploratory in nature, this interaction effect still need verification by future studies.

It has been increasingly recognized that left- and right-sided colorectal cancers have distinct clinical and molecular features which translates into different clinical outcomes\[[@B15],[@B16]\]. In our study, patients with right-sided primary tumor had worse PFS (adjusted HR = 1.87, 95%CI: 1.08--3.25, *P* = 0.03) and OS (adjusted HR = 1.92, 95%CI: 1.10--3.36, *P* = 0.02), adjusted for factors such as age and presence of liver-only diseases. The results were in line with the findings of the existing literature\[[@B17]\]. Apart from the poorer prognosis of the right-sided cancer, a retrospective pooled analysis of six randomized trials found out that the significant benefit for chemotherapy plus anti-*EGFR* antibody in *RAS* wild-type colorectal cancer could only be observed in left-sided tumors\[[@B18]\]. This also explained the worse prognosis of right-sided tumors in our patients receiving cetuximab as the first-line systemic therapy.

Another significant finding of the current study is that primary tumor resection appears to improve both the PFS (adjusted HR = 0.35, 95%CI: 0.21--0.59, *P* \< 0.01) and OS (adjusted HR = 0.37, 95%CI: 0.22--0.62, *P* \< 0.01). This was in accord with the existing evidence that palliative primary tumor resection was associated with improved survival\[[@B19]-[@B22]\]. Anyway, palliative primary tumor resection is still not a standard recommendation for asymptomatic mCRC as the improvement in survival has never been validated by a high-quality randomized trial yet\[[@B4],[@B5]\]. Apart from resection of primary tumor, liver-only disease was also shown to improve the PFS (adjusted HR = 0.57, 95%CI = 0.36--0.91, *P* = 0.02) and OS (adjusted HR = 0.58, 95%CI: 0.36--0.95, *P* = 0.03) significantly, which was also consistent with existing knowledge. Despite this was a Chinese-only cohort of patients, the sharing of known prognostic factors as in the reported literature supported similar tumor biology observed in our patients and consolidated the external validity of our findings that ethnicity may explain the differences in outcomes with regard to the combination of cetuximab and oral FP.

The adverse event profile of FP-based chemotherapy in combination with cetuximab was another main focus of our study. The frequency of adverse events of grade 3 or above in the cohort was 28.4% (Table [6](#T6){ref-type="table"}). This is far less than the reported figures in various clinical trials such as CRYSTAL (79.3%) and FIRE-3 (71.0%)\[[@B2],[@B23]\]. Haematological adverse events remained one of the commonest with this combination regimen. Non-haematological side effects of grade 3 or above were uncommon in our cohort. The frequency of grade 3 or above diarrhoea was 2.1%, which was also far lower than that observed in randomized controlled trials such as the MRC COIN trial (20% for fluorouracil-based therapy; 26% for capecitabine-based therapy) while it is similar to the findings in the Japanese FLEET study (5.4%)\[[@B6],[@B10],[@B11]\]. The toxicity patterns of both hematological and non-hematological adverse events did not differ between oral FP and infusional FP. These findings highlighted the regional differences in the tolerability profiles of FP. Haller et al\[[@B9]\] analyzed the safety data of three phase III studies that compared oral FP with infusional FP and suggested that East Asians had a better tolerability profile than Caucasians. This underlies the success of oral FP-based chemotherapy in combination with cetuximab in our cohort and in the FLEET study as well as the negative overall outcomes of the MRC COIN trial\[[@B6]\]. However, the apparently better tolerability may also be explained partly by the fact that patients in our cohort were younger (median age = 61 years) and upfront dose reduction was allowed for selected patients (75% dose for patients older than 70 years and/or creatinine clearance \< 50 mL/min).

Our study shared the limitations intrinsic to all retrospective analysis and the results should be considered hypothesis-generating rather than confirmatory. Due to the retrospective nature, we could not answer the underlying mechnism linking ethnicity and FP tolerability. We did not report the response rate in our patients as the assessment schedule and response evaluation would not be as stringent as in prospective clinical trial settings. Instead, we reported the more robust outcomes of PFS and OS which were less biased by assessment schedule and physicians' decision in the real-world setting. Selection bias is criticized for retrospective analysis but the results of our overall population was comparable to the reported literature, and that both treatment groups of oral FP and infusional FP served as internal control with balanced baseline characteristics. Adverse events were prone to under-reporting in the real-world setting but the effects should be the same in both oral and infusion FP groups and thus our conclusions should be considered as valid. The sample size of 95 in this study was small and did not have adequate power to detect subtle differences in outcomes. Nevertheless, the current cohort represented one of the largest that asked similar questions on this unmet clinical needs where there will unlikely be any further phase III randomized controlled trials.

The finding that combination of oral FP-based chemotherapy and cetuximab is a valid alternative to infusional FP in Chinese patients is important. It has been shown that oral fluoropyrimidine is more cost-effective and more preferred among patients\[[@B12]-[@B14]\]. In addition, infusional FP requires more hospital stay and venous access. Hence, the use of oral FP in combination with cetuximab may be beneficial to both patients and health services.

When combined with cetuximab, oral FP-based chemotherapy had a comparable safety and efficacy profile with infusional FP-based chemotherapy in Chinese population. The findings support oral FP as a valid option to combine with anti-EGFR mAb and call for reposition of such regimens for Asian patients in both regional and international guidelines.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Although cetuximab is shown to provide survival benefits in patients with *RAS* wild-type metastatic colorectal cancer, little is known about the optimal chemotherapy backbone for cetuximab except that oral fluoropyrimidine appeared to be inferior to infusional fluoropyrimidine and is not recommended in various international guidelines.

Research motivation
-------------------

Before the evidence of the inferiority of oral fluoropyrimidine combining with cetuximab, it was commonly used due to convenience and cost effectiveness. The inferiority of oral fluoropyrimidine was not readily observed in our previous experience. In addition, research has shown that there might be a regional difference in the tolerability of oral fluopyrimidine. The inferiority of oral fluopyrimidine demonstrated in previous studies might not be applicable to our locality with Chinese population.

Research objectives
-------------------

This study would like to compare oral fluoropyrimidine with infusional fluoropyrimidine in combination with cetuximab in Chinese population in terms of progression-free survival and overall survival.

Research methods
----------------

A retrospective cohort study was employed to compare and contrast the survival and adverse effect profile of oral fluoropyrimidine (FP) and infusional FP in combination with cetuximab in Chinese population in the real-world setting.

Research results
----------------

There was no significant difference in median progression-free survival and median overall survival between the two groups. The incidence of various grade 3 or above adverse effects was similar in both groups.

Research conclusions
--------------------

Oral and infusional fluoropyrimidine has comparable efficacy and safety profiles when used with cetuximab.

Research perspectives
---------------------

Oral fluoropyrimidine may be a good alternative to infusional fluoropyrimidine when in combination with cetuximab.
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